Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Accumulated Expenses (2020 - 2023)

Historic Other Accumulated Expenses for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $48000.0.

  • Candel Therapeutics' Other Accumulated Expenses rose 5483.87% to $48000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $48000.0, marking a year-over-year increase of 5483.87%. This contributed to the annual value of $48000.0 for FY2022, which is 8562.87% down from last year.
  • Per Candel Therapeutics' latest filing, its Other Accumulated Expenses stood at $48000.0 for Q3 2023, which was up 5483.87% from $48000.0 recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Other Accumulated Expenses ranged from a high of $334000.0 in Q4 2021 and a low of $31000.0 during Q3 2022
  • For the 4-year period, Candel Therapeutics' Other Accumulated Expenses averaged around $123090.9, with its median value being $63000.0 (2022).
  • As far as peak fluctuations go, Candel Therapeutics' Other Accumulated Expenses soared by 7860.96% in 2021, and later plummeted by 8646.29% in 2022.
  • Candel Therapeutics' Other Accumulated Expenses (Quarter) stood at $187000.0 in 2020, then skyrocketed by 78.61% to $334000.0 in 2021, then plummeted by 85.63% to $48000.0 in 2022, then changed by 0.0% to $48000.0 in 2023.
  • Its last three reported values are $48000.0 in Q3 2023, $48000.0 for Q2 2023, and $48000.0 during Q1 2023.